M. Sałaga

发表

Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain

J. Fichna, M. Włodarczyk, A. Zielińska, 2018, International Journal of Colorectal Disease.

Orally available extract from Brassica oleracea var. capitata rubra attenuates experimental colitis in mouse models of inflammatory bowel diseases

W. Krajewska, R. Kordek, J. Fichna, 2015 .

Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors.

W. Krajewska, R. Kordek, J. Fichna, 2014, Biochemical pharmacology.

Immunopharmacology and in fl ammation Anti-in fl ammatory effect of dual nociceptin and opioid receptor agonist , BU 08070 , in experimental colitis in mice

R. Kordek, J. Fichna, S. Husbands, 2015 .

Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice

R. Kordek, J. Fichna, J. Timmermans, 2017, Naunyn-Schmiedeberg's Archives of Pharmacology.

Expression of FFAR3 and FFAR4 Is Increased in Gastroesophageal Reflux Disease

J. Fichna, A. Mokrowiecka, E. Małecka-Panas, 2020, Journal of clinical medicine.

Dietary fatty acid content influences the expression of genes involved in the lipid turnover and inflammation in mouse colon and spleen

J. Fichna, A. Fabisiak, Aleksandra Tarasiuk, 2019, Pharmacological reports : PR.

Activation of Free Fatty Acid Receptor 4 Affects Intestinal Inflammation and Improves Colon Permeability in Mice

R. Kordek, J. Fichna, A. Fabisiak, 2021, Nutrients.

Free Fatty Acid Receptors as new potential target in Colorectal Cancer.

J. Fichna, A. Fabisiak, Aleksandra Tarasiuk, 2019, Current drug targets.

Free Fatty Acid Receptors as new potential therapeutic target in Inflammatory Bowel Diseases.

J. Fichna, K. Martemyanov, A. Fabisiak, 2019, Pharmacological research.

Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract.

J. Fichna, M. Sobczak, M. Sałaga, 2013, Drug discovery today.

Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.

J. Fichna, M. Sobczak, M. Sałaga, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

AdipoRon, an Orally Active, Synthetic Agonist of AdipoR1 and AdipoR2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice

R. Kordek, J. Fichna, K. Majchrzak, 2021, Molecules.

Activation of the endogenous nociceptin system by selective nociceptin receptor agonist SCH 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrhea‐predominant IBS

W. Krajewska, J. Timmermans, M. Storr, 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Characterization of the effects of opiorphin and sialorphin and their analogs substituted in position 1 with pyroglutamic acid on motility in the mouse ileum

J. Fichna, W. Kamysz, E. Kamysz, 2013, Journal of peptide science : an official publication of the European Peptide Society.

FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue‐derived hormone levels in mouse models mimicking constipation‐predominant IBS

W. Krajewska, J. Fichna, J. Timmermans, 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Experimental colitis in mice is attenuated by topical administration of chlorogenic acid

R. Kordek, J. Fichna, U. Lewandowska, 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

Pharmacological Treatment of Peptic Ulcer Disease

M. Sałaga, P. Mosińska, 2017 .

Walnut Oil Alleviates Intestinal Inflammation and Restores Intestinal Barrier Function in Mice

A. Bartoszek, R. Kordek, J. Fichna, 2020, Nutrients.

Lysophosphatidylcholine and its phosphorothioate analogues potentiate insulin secretion via GPR40 (FFAR1), GPR55 and GPR119 receptors in a different manner

E. Gendaszewska-Darmach, H. Kristinsson, P. Bergsten, 2017, Molecular and Cellular Endocrinology.

Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome

J. Fichna, A. Kowalczuk, M. Sałaga, 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

Salvinorin A analogues PR‐37 and PR‐38 attenuate compound 48/80‐induced itch responses in mice

B. Roth, J. Fichna, J. Do Régo, 2015, British journal of pharmacology.

Cyclic derivative of morphiceptin Dmt-cyclo-(D-Lys-Phe-D-Pro-Asp)-NH2(P-317), a mixed agonist of MOP and KOP opioid receptors, exerts anti-inflammatory and anti-tumor activity in colitis and colitis-associated colorectal cancer in mice.

W. Krajewska, R. Kordek, J. Fichna, 2020, European journal of pharmacology.

Role of glucagon-like peptides in inflammatory bowel diseases—current knowledge and future perspectives

J. Fichna, H. Zatorski, M. Sałaga, 2019, Naunyn-Schmiedeberg's Archives of Pharmacology.

Colonic inflammation induces changes in glucose levels through modulation of incretin system

W. Krajewska, J. Fichna, A. Mokrowiecka, 2021, Pharmacological Reports.

New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration

R. Kordek, J. Fichna, A. Mokrowiecka, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Anti-Inflammatory and Antinociceptive Action of an Orally Available Nociceptin Receptor Agonist SCH 221510 in a Mouse Model of Inflammatory Bowel Diseases

W. Krajewska, R. Kordek, J. Fichna, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Recent advances in inflammatory bowel disease therapy.

J. Fichna, M. Sałaga, A. Binienda, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The 25(OH)D3, but Not 1,25(OH)2D3 Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency

J. Fichna, A. Zielińska, A. Gąsiorowska, 2021, Pharmaceuticals.

Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives

J. Fichna, M. Storr, M. Sobczak, 2013, Journal of Gastroenterology.

Endocannabinoid System

J. Fichna, M. Sałaga, Aleksandra Tarasiuk, 2020, Encyclopedia of Gastroenterology.

Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice

R. Kordek, J. Fichna, M. Storr, 2016, Naunyn-Schmiedeberg's Archives of Pharmacology.

The cannabinoid‐1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice

M. Storr, A. Sibaev, M. Sobczak, 2013, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review

J. Fichna, M. Sałaga, P. Mosińska, 2016, Expert opinion on investigational drugs.

Anti-inflammatory and antinociceptive action of the dimeric enkephalin peptide biphalin in the mouse model of colitis: New potential treatment of abdominal pain associated with inflammatory bowel diseases

J. Fichna, A. Lipkowski, M. Sobczak, 2014, Peptides.

Endocannabinoid and Cannabinoid-Like Fatty Acid Amide Levels Correlate with Pain-Related Symptoms in Patients with IBS-D and IBS-C: A Pilot Study

P. Oprocha, A. Makriyannis, W. Krajewska, 2013, PloS one.

The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome

A. Makriyannis, J. Fichna, M. Storr, 2018, European journal of pharmacology.

Cannabis and Cannabinoids and the Effects on Gastrointestinal Function: An Overview

J. Fichna, R. Abalo, M. Sałaga, 2017 .

Cross-talk between serotonin and cannabinoid signaling in the gut, new insights and future perspectives

J. Fichna, M. Storr, M. Sałaga, 2014, PAIN®.

Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH).

H. Bradshaw, W. Krajewska, R. Kordek, 2014, Journal of Crohn's & colitis.

Anti-Inflammatory Effect of Homo- and Heterodimers of Natural Enkephalinase Inhibitors in Experimental Colitis in Mice

J. Fichna, E. Kamysz, M. Sałaga, 2020, Molecules.

Systemic Administration of Sialorphin Attenuates Experimental Colitis in Mice via Interaction With Mu and Kappa Opioid Receptors

W. Krajewska, R. Kordek, J. Fichna, 2017, Journal of Crohn's & colitis.

Silver nanoparticles based on blackcurrant extract show potent anti-inflammatory effect in vitro and in DSS-induced colitis in mice.

J. Fichna, M. Banach, O. Długosz, 2020, International journal of pharmaceutics.

Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid‐like fatty acid amides

D. Saur, H. Bradshaw, J. Fichna, 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Pharmacological and Clinical Treatment of Irritable Bowel Syndrome

M. Sałaga, P. Mosińska, 2017 .

Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system

W. Krajewska, R. Kordek, J. Fichna, 2019, Biochemical pharmacology.

[Genetic factors in pathogenesis, course and treatment of inflammatory bowel diseases].

J. Fichna, H. Zatorski, M. Sałaga, 2015, Postepy higieny i medycyny doswiadczalnej.

Czynniki genetyczne w patogenezie, przebiegu i leczeniu nieswoistych chorób zapalnych jelit* Genetic factors in pathogenesis, course and treatment of inflammatory bowel diseases

J. Fichna, H. Zatorski, M. Sałaga, 2015 .

Chinese Herbal Medicines in the Treatment of IBD and Colorectal Cancer: A Review

J. Fichna, M. Sobczak, H. Zatorski, 2014, Current Treatment Options in Oncology.

Current overview of colitis-associated colorectal cancer

J. Fichna, M. Sobczak, Marcin Wlazłowski, 2014, Central European Journal of Biology.

Orally administered novel cyclic pentapeptide P‐317 alleviates symptoms of diarrhoea‐predominant irritable bowel syndrome

W. Krajewska, J. Fichna, P. Wlaź, 2015, The Journal of pharmacy and pharmacology.

Anti-inflammatory action of a novel orally available peptide 317 in mouse models of inflammatory bowel diseases

W. Krajewska, R. Kordek, J. Fichna, 2014, Pharmacological reports : PR.

Preventing Bacterial Translocation in Patients with Leaky Gut Syndrome: Nutrition and Pharmacological Treatment Options

J. Fichna, M. Sałaga, A. Binienda, 2022, International journal of molecular sciences.

Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis.

A. Giełdoń, J. Fichna, E. Kamysz, 2016, Future medicinal chemistry.

Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.

J. Fichna, S. Husbands, M. Sobczak, 2014, European journal of pharmacology.

Nociceptin / orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases.

J. Fichna, M. Storr, M. Sobczak, 2013, Current drug targets.

Mixed MOP/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms

J. Fichna, A. Lipkowski, M. Sałaga, 2016, Pharmacological reports : PR.

Chronic abdominal pain in irritable bowel syndrome – current and future therapies

J. Fichna, M. Włodarczyk, A. Zielińska, 2018, Expert review of clinical pharmacology.

Characterization of the Synergistic Effect between Ligands of Opioid and Free Fatty Acid Receptors in the Mouse Model of Colitis

R. Kordek, J. Fichna, A. Fabisiak, 2021, Molecules.

The Role of Oxidative Stress in the Pathophysiology of Gastrointestinal Disorders

J. Fichna, M. Sałaga, P. Mosińska, 2017 .

Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH2) with anti-inflammatory activity in the mouse models of colitis

R. Kordek, J. Fichna, P. Kosson, 2018, Peptides.

RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives

J. Fichna, M. Storr, K. Martemyanov, 2016, BioEssays : news and reviews in molecular, cellular and developmental biology.

Genetic aspect (with SNPs) of irritable bowel syndrome

M. Sałaga, A. Binienda, Agata Binienda, 2020 .

Dietary Carbohydrates and Lipids in the Pathogenesis of Leaky Gut Syndrome: An Overview

M. Sałaga, A. Binienda, Adam Makaro, 2020, International journal of molecular sciences.

High activity of endogenous opioid system protects against gastric damage development in mouse models of gastric mucosal injury

J. Fichna, A. Misicka, A. Wasilewski, 2019, Pharmacological reports : PR.

Pharmacological approaches to treat intestinal pain

M. Sałaga, Adam Makaro, Mikolaj Swierczynski, 2023, Expert review of clinical pharmacology.

Empagliflozin attenuates intestinal inflammation through suppression of nitric oxide synthesis and myeloperoxidase activity in in vitro and in vivo models of colitis

R. Kordek, J. Fichna, M. Sałaga, 2023, Inflammopharmacology.

Management of pain in colorectal cancer patients.

J. Fichna, M. Włodarczyk, A. Zielińska, 2020, Critical reviews in oncology/hematology.

Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.

J. Fichna, M. Storr, M. Sałaga, 2017, Current drug targets.

Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice

R. Kordek, J. Fichna, M. Storr, 2016, Naunyn-Schmiedeberg's Archives of Pharmacology.

UEG Young Talent Group: What do we do?

U. Nitsche, H. Heinrich, M. Sałaga, 2019, United European gastroenterology journal.

Novel glycosylated endomorphin-2 analog produces potent centrally-mediated antinociception in mice after peripheral administration.

J. Fichna, A. Janecka, W. Kamysz, 2013, Bioorganic & medicinal chemistry letters.

Encenicline, an α7 Nicotinic Acetylcholine Receptor Partial Agonist, Reduces Immune Cell Infiltration in the Colon and Improves Experimental Colitis in Mice

W. Krajewska, J. Fichna, A. Piechota-Polańczyk, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Experimental colitis in mice is attenuated by topical administration of chlorogenic acid

R. Kordek, J. Fichna, U. Lewandowska, 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

Neuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in mice

J. Fichna, P. Wlaź, A. Kowalczuk, 2016, Metabolic Brain Disease.

Polyphenol extract from evening primrose pomace alleviates experimental colitis after intracolonic and oral administration in mice

W. Krajewska, J. Fichna, U. Lewandowska, 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

Role of Transient Receptor Potential Channels in Intestinal Inflammation and Visceral Pain: Novel Targets in Inflammatory Bowel Diseases

J. Fichna, A. Wasilewski, M. Sałaga, 2015, Inflammatory bowel diseases.

Oxidative Stress Does Not Influence Subjective Pain Sensation in Inflammatory Bowel Disease Patients

A. Dziki, J. Fichna, M. Włodarczyk, 2021, Antioxidants.

Clinical Features of Irritable Bowel Syndrome

M. Sałaga, P. Mosińska, 2017 .

RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives

J. Fichna, M. Storr, K. Martemyanov, 2016, BioEssays : news and reviews in molecular, cellular and developmental biology.

Novel Orally Available Salvinorin A Analog PR-38 Inhibits Gastrointestinal Motility and Reduces Abdominal Pain in Mouse Models Mimicking Irritable Bowel Syndrome

J. Fichna, A. Sibaev, W. Kamysz, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.

J. Fichna, M. Sobczak, M. Sałaga, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The cannabinoid‐1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice

A. Sibaev, M. Sobczak, M. Sałaga, 2013, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice.

R. Kordek, J. Fichna, S. Husbands, 2015, European journal of pharmacology.

Characterization of the effects of opiorphin and sialorphin and their analogs substituted in position 1 with pyroglutamic acid on motility in the mouse ileum

J. Fichna, W. Kamysz, E. Kamysz, 2013, Journal of peptide science : an official publication of the European Peptide Society.

Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome

J. Fichna, A. Kowalczuk, M. Sałaga, 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

Regulators of G-Protein Signaling (RGS) in Sporadic and Colitis-Associated Colorectal Cancer

M. Sałaga, Adam Makaro, Mikolaj Swierczynski, 2024, International journal of molecular sciences.

Neuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in mice

J. Fichna, P. Wlaź, A. Kowalczuk, 2016, Metabolic Brain Disease.